Hypercalcemia, which was present in 31% of our patients at baseline, is a hallmark of progressive myeloma and is known to impair renal function by decreasing the sensitivity of collecting ducts to antidiuretic hormone, reducing sodium reabsorption, increasing diuresis, and constricting afferent arterioles. This evidence concerns the gene AVP and Hypercalcemia.